New research · OphthalmologyBrachytherapy · 17hCohort studyBrachytherapy · 2026Low dose iodine-125 brachytherapy and transpupillary thermal therapy for small- to medium-sized choroidal melanoma.S Fattahi, C L Deufel, K V Astafurov … K S Corbin +7 moreRead paper Copy citationOphthalmologyCohort studyModerate evidenceReduced-dose iodine-125 brachytherapy gave 0% local tumor recurrence at 5 years.Low dose iodine-125 brachytherapy and transpupillary thermal therapy for small- to medium-sized choroidal melanoma.S Fattahi … K S CorbinBrachytherapy · 2026BackgroundCOMS established iodine-125 ( 125 I) brachytherapy as standard of care for medium-sized choroidal melanomas.PurposeCOMS established iodine-125 ( 125 I) brachytherapy as standard of care for medium-sized choroidal melanomas.MethodsDiagnosed 2005-2019 with choroidal melanoma <5 mm thick and managed with 125 I brachytherapy dose of 65 Gy to depth of 5 mm were included.n = 143 patients0%Results🎯 Predict0%no tumors regrew locally within 5 years of treatmentn = 143 patientsMore resultsFive-year Kaplan-Meier estimates of ocular adverse events were 59.6% radiation maculopathy, 42.0% cystoid macular edema, 55.2% nonproliferative radiation retinopathy, 10.8% proliferative radiation retinopathy, and 35.6% radiation papillopathy.“ConclusionReduced dose 125 I brachytherapy is feasible with excellent local tumor control.Read full abstractRead paper LikeCommentRepostSendPractice